| ‘Doctor, can I stop my medicine?’Analysis of disease course after stopping disease-modifying therapy in stable MS patients (P5. 192) I Kister, T Spelman, P Duquette, M Girard, J Lechner-Scott, ... Neurology 84 (14_supplement), P5. 192, 2015 | 5 | 2015 |
| “Rocking the boat” with a new drug for neuromyelitis optica spectrum disorder M Levy, J Lechner-Scott, C Hawkes, G Giovannoni Multiple Sclerosis and Related Disorders 44, 2020 | | 2020 |
| [Retracted] Prediction of Conversion from CIS to Clinically Definite Multiple Sclerosis Using Convolutional Neural Networks HMR Afzal, S Luo, S Ramadan, M Khari, G Chaudhary, J Lechner-Scott Computational and Mathematical Methods in Medicine 2022 (1), 5154896, 2022 | 4 | 2022 |
| 002 Therapeutic lag in relapsing multiple sclerosis I Roos, F Frascoli, J Lechner-Scott, P McCombe, R Macdonell, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (e7), A1-A1, 2019 | | 2019 |
| 004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis WZ Yeh, PA Widyastuti, A Van der Walt, J Stankovich, EK Havrdova, ... BMJ Neurology Open 3 (Suppl 1), 2021 | | 2021 |
| 006 Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models I Diouf, CB Malpas, S Sharmin, O Skibina, K Buzzard, J Lechner-Scott, ... BMJ Neurology Open 3 (Suppl 1), 2021 | | 2021 |
| 008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis I Roos, CB Malpas, E Leray, K Buzzard, O Skibina, J Lechner-Scott, ... BMJ Neurology Open 3 (Suppl 1), 2021 | | 2021 |
| 010 Real-world experience with ocrelizumab in the MSBase registry–Australian RRMS cohort H Butzkueven, T Spelman, T Kalincik, K Buzzard, A Van der Walt, ... BMJ Neurology Open 3 (Suppl 1), 2021 | | 2021 |
| 011 Worsening longitudinal reaction time trajectories using the MSReactor computerised battery predicts confirmed EDSS progression D Merlo, J Stankovich, C Bai, T Kalincik, M Gresle, J Lechner-Scott, ... BMJ Neurology Open 3 (Suppl 1), 2021 | | 2021 |
| 028 Treating progressive multiple sclerosis J Hughes, V Jokubaitis, M Slee, J Lechner-Scott, A Van der Walt, ... Journal of Neurology, Neurosurgery & Psychiatry 89 (6), A12-A12, 2018 | | 2018 |
| 065 A pilot time and motion study for treatments of relapsing remitting multiple sclerosis (RRMS) in australia J Lechner-Scott, R Davey, P Davey, G Bogeski, E Cheah Journal of Neurology, Neurosurgery & Psychiatry 89 (6), A26-A27, 2018 | | 2018 |
| 068 Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study T Sprenger, J Lechner-Scott, MP Sormani, JS Wolinsky, J Wuerfel, ... Journal of Neurology, Neurosurgery & Psychiatry 89 (6), A28-A28, 2018 | 6 | 2018 |
| 1 Patient-determined disease steps is not equivalent to the expanded disability status scale in mild to moderate multiple sclerosis YC Foong, D Merlo, M Gresle, C Zhu, K Buzzard, J Lechner-Scott, ... BMJ Neurology Open 5 (Suppl 1), 2023 | | 2023 |
| 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort VG Jokubaitis, T Spelman, T Kalincik, D Travaglini, D Paolicelli, ... Multiple Sclerosis Journal 21, 100-102, 2015 | | 2015 |
| 12.: Natural killer cell subset patterns on established treatments for multiple sclerosis P Caruana, K Lemmert, R Lea, J Lechner-Scott Journal of Clinical Neuroscience 21 (11), 2036-2037, 2014 | | 2014 |
| 131 CLADIN: CLADribine and INnate immune responses M Monif, S Abdollahi, J Stankovich, V Maltby, J Lechner-Scott, T Kalincik, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (e7), A42-A42, 2019 | | 2019 |
| 134 Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS) J Lechner-Scott, V Maltby, A Lyndon, M Monif, T Kilpatrick, H Butzkueven, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (e7), A43-A43, 2019 | | 2019 |
| 22. Enterovirus meningitis in a patient treated with Natalizumab T Wellings, J Lechner-Scott Journal of Clinical Neuroscience 16 (11), 1531-1532, 2009 | | 2009 |
| 2242 Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis I Roos, S Sharmin, J Lechner-Scott, K Buzzard, O Skibina, A van der Walt, ... BMJ Neurology Open 4 (Suppl 1), 2022 | | 2022 |
| 2258 Novel generation of real-world evidence through MSGo, a digital support program supporting the use of siponimod in secondary progressive multiple sclerosis patients in … T Hardy, P Aouad, S Blum, S Broadley, W Carroll, D Crimmins, D Griffiths, ... BMJ Neurology Open 4 (Suppl 1), 2022 | | 2022 |
